City of Edinburgh Council as A v. Pfizer Inc
754 F.3d 159
3rd Cir.2014Background
- Plaintiffs (two institutional funds) sued Wyeth (now Pfizer) and four former Wyeth executives alleging securities fraud based on public statements about interim Phase 2 clinical data for the Alzheimer’s drug bapineuzumab; class period: May 21, 2007–July 29, 2008.
- Central public statement: May 21, 2007 joint release announcing intent to initiate Phase 3 “based on the seriousness of the disease and the totality of what the companies have learned…, including a scheduled Interim look at data from an ongoing Phase 2 study, which remains blinded,” and cautioning no conclusion should be drawn until study completion.
- Plaintiffs rely on two confidential witnesses who say the Phase 2 interim results failed pre-specified efficacy p-values, showed no dose response, and revealed safety issues; plaintiffs allege these facts made Wyeth’s statements false or misleading and that some insiders traded contemporaneously.
- Wyeth responded that the interim data showed ‘‘circumstantial evidence of efficacy’’ for an ApoE4 non-carrier subgroup and that the May 2007 Release merely listed the interim look as one factor among several and expressly warned the study remained blinded.
- The District Court twice dismissed the complaint under Rule 12(b)(6) for failure to plead falsity and no duty to disclose; plaintiffs appealed; the Third Circuit affirmed dismissal, holding plaintiffs failed to plead actionable misrepresentations/omissions or required scienter for control-person and insider-trading claims.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether May 21, 2007 Release contained an affirmative false statement that Phase 3 decision was "based on" interim Phase 2 results | May: Wyeth actually proceeded despite interim results that failed pre-specified criteria; statement was false | Wyeth: "based on" means interim results were one factor among others; Release contained no affirmative characterization of strength | Court: Held not false; plaintiffs failed PSLRA particularity and showed only disagreement about interpretation |
| Whether prior Ruffolo “spectacular” remark rendered the May 2007 Release misleading (duty to correct/update) | May: Ruffolo set expectation that Phase 3 would not start early unless interim results were “spectacular,” so silence was misleading | Wyeth: Ruffolo’s comment was conditional, forward-looking, puffery, and superseded by the May 2007 Release which cautioned no conclusions | Court: Held not misleading; no duty to update; statement was puffery/conditional and Release tempered it |
| Whether later public statements (post–May 21) omitted material adverse interim data or otherwise were misleading | May: Subsequent remarks repeated the omission and failed to disclose negative interim metrics and safety problems | Wyeth: Later statements consistently noted the interim look was blinded, reiterated caution, or were non-actionable puffery; June 2008 disclosures already addressed final results | Court: Held plaintiffs failed to plead falsity for post–May 21 statements; June 2008 Release not challenged on duty-to-disclose ground |
| Whether plaintiffs pleaded insider trading/ control-person liability (scienter and predicate 10(b) violation) | May: Executives (Ruffolo, Martin) sold stock/options knowing negative interim data, supporting scienter and 20A/20(a) claims | Wyeth: Plaintiffs failed to plead a predicate 10(b) violation and failed to plead a strong inference of scienter; stock sales alone insufficient | Court: Held plaintiffs failed to plead predicate Exchange Act violation and strong inference of scienter; 20A and 20(a) dismissed |
Key Cases Cited
- Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (2007) (PSLRA requires pleading facts giving rise to a "strong inference" of scienter and courts must evaluate competing inferences)
- Matrixx Initiatives, Inc. v. Siracusano, 131 S. Ct. 1309 (2011) (omissions can render statements misleading when omitted information would be viewed by a reasonable investor as material)
- Kleinman v. Elan Corp., plc, 706 F.3d 145 (2d Cir. 2013) (statements describing subgroup results as "encouraging" were non-actionable puffery and omissions failed to render June 2008 release false)
- Institutional Investors Group v. Avaya, Inc., 564 F.3d 242 (3d Cir. 2009) (PSLRA particularity standard applied to confidential witness allegations and scienter analysis)
- Cal. Pub. Emps.’ Ret. Sys. v. Chubb Corp., 394 F.3d 126 (3d Cir. 2004) (court must consider statements in full context; confidential-witness evidence must be assessed for consistency with public statements)
- In re Advanta Corp. Sec. Litig., 180 F.3d 525 (3d Cir. 1999) (vague optimistic statements constitute non-actionable puffery)
- In re Burlington Coat Factory Sec. Litig., 114 F.3d 1410 (3d Cir. 1997) (contextual reading of corporate statements required; duty to update limited to narrow circumstances)